T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production

Metastatic renal cell carcinoma (RCC) has a poor prognosis. Recent advances have shown beneficial responses to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies. As only a subset of RCC patients respond, alternative strategies should be explored. Patients refractory to anti-PD-1 thera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: van Asten, Saskia D., de Groot, Rosa, van Loenen, Marleen M., Castenmiller, Suzanne M., de Jong, Jeroen, Monkhorst, Kim, Haanen, John B.A.G., Amsen, Derk, Bex, Axel, Spaapen, Robbert M., Wolkers, Monika C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7833735/
https://ncbi.nlm.nih.gov/pubmed/33537169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1860482
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge